Literature DB >> 32300960

Long non-coding RNA MIAT promotes the growth of melanoma via targeting miR-150.

Lifei Zhu1, Yexiao Wang2, Chaoying Yang1, Yanchang Li1, Zhixin Zheng1, Liangcai Wu3, Hui Zhou4.   

Abstract

Melanoma is a common skin cancer and it can lead to high mortality probably by early invasion and metastasis. LncRNA MIAT is involved in tumor proliferation, invasion and epithelial-to-mesenchymal transition (EMT). However, the roles of MIAT in melanoma still require further investigation. Thus, the aim of the study is to investigate the roles of MIAT in melanoma, especially the effects of MIAT on EMT of melanoma cancer cells. The results showed that the expression of MIAT was significantly upregulated in melanoma tissue and cells compared with the normal skin and normal melanocytes; moreover, miR-150 was confirmed as a target of MIAT. Furthermore, knockdown of MIAT inhibited cell proliferation and invasion in melanoma cancer cells and transfection of miR-150 inhibitors partial abrogated the anti-tumor effects of MIAT siRNA. In addition, MIAT siRNA also inhibited the EMT of melanoma cells, while miR-150 inhibitors can reverse the effects of MIAT siRNA. Finally, knockdown of MIAT also inhibited the carcinogenic effects of melanoma in vivo by targeting miR-150. In conclusion, we reported that MIAT promotes the proliferation, invasion and EMT of melanoma cells via targeting miR-150, which suggested that MIAT might be a therapeutic target for the treatment of melanoma.

Entities:  

Keywords:  EMT; MIAT; Melanoma; miR-150

Mesh:

Substances:

Year:  2020        PMID: 32300960     DOI: 10.1007/s13577-020-00340-y

Source DB:  PubMed          Journal:  Hum Cell        ISSN: 0914-7470            Impact factor:   4.374


  6 in total

1.  Increasing miR-150 and lowering HMGA2 inhibit proliferation and cycle progression of colon cancer in SW480 cells.

Authors:  Z-C Zhang; G-P Wang; L-M Yin; M Li; L-L Wu
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-10       Impact factor: 3.507

2.  Long non-coding RNA MIAT promotes non-small cell lung cancer progression by sponging miR-1246.

Authors:  D Lin; H-P Xu; J-H Lin; H-H Hu; Q Wang; J Zhang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2019-07       Impact factor: 3.507

3.  MiR-150 alleviates EMT and cell invasion of colorectal cancer through targeting Gli1.

Authors:  H Fan; X Liu; W-W Zheng; Z-H Zhuang; C-D Wang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2017-11       Impact factor: 3.507

4.  Knockdown of lncRNA-UCA1 inhibits the proliferation and migration of melanoma cells through modulating the miR-28-5p/HOXB3 axis.

Authors:  Chaofei Han; Fengjie Tang; Jia Chen; Dan Xu; Xiong Li; Yangcheng Xu; Shaohua Wang; Jianda Zhou
Journal:  Exp Ther Med       Date:  2019-03-20       Impact factor: 2.447

5.  LncRNA HAND2-AS1 promotes liver cancer stem cell self-renewal via BMP signaling.

Authors:  Yanying Wang; Pingping Zhu; Jianjun Luo; Jing Wang; Zhiwei Liu; Wei Wu; Ying Du; Buqing Ye; Dongpeng Wang; Lei He; Weizheng Ren; Jianyi Wang; Xianhui Sun; Runsheng Chen; Yong Tian; Zusen Fan
Journal:  EMBO J       Date:  2019-07-23       Impact factor: 11.598

6.  Long noncoding RNA DSCAM-AS1 is associated with poor clinical prognosis and contributes to melanoma development by sponging miR-136.

Authors:  Y-L Huang; Q Xu; X Wang
Journal:  Eur Rev Med Pharmacol Sci       Date:  2019-04       Impact factor: 3.507

  6 in total
  2 in total

1.  LncRNA MIAT promotes the proliferation, migration, and invasion of melanoma cells through recruiting TCF12 and activating NFAT5.

Authors:  Fei Lu; Ying Song; Shuo Cui; Huafei Zhao; Yuhua Chen; Hao Du
Journal:  Am J Transl Res       Date:  2021-11-15       Impact factor: 4.060

Review 2.  The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma.

Authors:  Barbara Montico; Giorgio Giurato; Giovanni Pecoraro; Annamaria Salvati; Alessia Covre; Francesca Colizzi; Agostino Steffan; Alessandro Weisz; Michele Maio; Luca Sigalotti; Elisabetta Fratta
Journal:  Mol Oncol       Date:  2021-06-18       Impact factor: 6.603

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.